Pharmacy Times

JULY 2, 2025

Medication adherence is hard, so we haven't tracked medication adherence, but it is definitely something that for every patient we are looking at, we are trying to help them with. We're tracking pharmacist interventions to see what all the pharmacist is doing with each patient and looking at cost savings that go along with that.

Pharmacy Technician

Pharmacy Times

JULY 16, 2025

These trials varied in their definitions of severe CAP, corticosteroids used, primary outcomes, and results. Investigators included patients with severe CAP based on the ATS/IDSA definition ( Table 2 ) and excluded those with previous use of steroids and vasopressor-dependent shock. BMJ Open Respir Res. 2024;11(1):e002141.

Pharmacy Technician

Putting Patients First Blog

JUNE 26, 2025

11 The role of patient-centered evidence in the renegotiation process also requires greater definition. For example, long-acting formulations, less painful injection methods, and fixed-dose combination therapies have each played a critical role in improving adherence and outcomes in conditions such as diabetes, autoimmune diseases, and HIV.

Drug Pricing

Pharmacy Times

JULY 3, 2025

That is something we have definitely taken from transplant and shared with our other bispecific programs—especially now that we do bispecifics in solid tumors.

Inpatient

Pharmacy Times

JUNE 9, 2025

I’m coming at it from the perspective of understanding the science behind it… When you talk about manipulating genes, that definitely tends to put some people off,” she said. “I Trinkman noted the hesitancy some patients have shown toward gene therapies, emphasizing the need for greater education about how these therapies work.

Pharmacy Technician

Pharmacy Times

JULY 17, 2025

8 By these definitions, more patients experiencing homelessness were sheltered than unsheltered ( Table 3 ). Finerenone and the Future of Diabetes-Related Kidney Care Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

HIV Treatment and Prevention Agents

STAT

FEBRUARY 25, 2025

In recent years, an idea has taken hold across the ideological spectrum: The rise in diabetes and obesity in the United States is attributable to addictive, ultra-processed foods that dominate the American diet. Ultra-processed foods include everything from chips to nutrition supplement smoothies to breakfast cereals to chicken stock.

Diabetes

Pharmaceutical Commerce

JULY 16, 2025

The allure of compounded alternatives: A closer look at the "gold rush" The intense demand for GLP-1 agonists stems from their proven efficacy in managing type 2 diabetes and, increasingly, in facilitating significant weight loss. This gap in the market has created a "gold rush" for compounding pharmacies and new startups.

Compounding

Pharmacy Times

JULY 18, 2025

The definition of "essentially a copy" is pivotal, influencing compounding practices and legal interpretations. Finerenone and the Future of Diabetes-Related Kidney Care Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Compounding

Putting Patients First Blog

JUNE 16, 2025

These limitations stem from both definitional exclusions and inconsistent implementation. LaManna, and Chanhyun Park, “Digital Divide Among Medicare Beneficiaries and the Diabetes Prevention Program,” American Journal of Preventive Medicine 67, no. CMS can accelerate access by: Expanding Blue Button 2.0 27] Kelly J.

Documentation

Pharmacy Times

JULY 9, 2025

As evidence evolves, pharmacists can lead in translating research into practice—implementing screening, personalized dosing, and interprofessional coordination while awaiting definitive trial results. 1-4 REFERENCES 1. Jiang Y, Dang W, Sui L, et al. Associations Between Vitamin D and Core Symptoms in ASD: An umbrella review. 2024;16:59–91.

Pharmacy Technician

Pharmacy Times

JUNE 12, 2025

1,2 The primary end point was event-free survival (EFS), which was defined as the time from randomization to the first occurrence of disease progression precluding definitive surgery, local or distant disease progression or recurrence, or death due to any cause. The key secondary end point was overall survival (OS). months (95% CI: 37.9,

Pharmacy Technician

Pharmacy Times

JUNE 6, 2025

Klein: In terms of the management of pericarditis and recurrent pericarditis, let me just go through definitions. Are there specific comorbidities or patient characteristics that influence your decision? Acute pericarditis is the inflammation of the lining of the heart.

Pharmacy Technician

Express Pharma

JULY 8, 2025

In these times of increased social interactions, the transient nature of trends and the constant need to fit in, the definition of beauty is changing. While once you went gaga over that latest face cream or lipstick, times have changed – from altering your complexion, to even your metabolism – pills and needles are the new go-to.

Labelling

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunity

STAT

JULY 6, 2023

Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study. The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites.

Diabetes

pharmaphorum

JULY 3, 2025

Skip to main content Thursday 3 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

PharmExec

DECEMBER 4, 2023

Roche announces definitive merger agreement to acquire Carmot Therapeutics, Inc., which has an R&D portfolio that includes clinical stage subcutaneous and oral incretins for the treatment of patients with obesity, both with and without diabetes.

Diabetes

Med Ed 101

NOVEMBER 22, 2020

Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The post Two Diabetes Updates in 2020 appeared first on Med Ed 101.

Diabetes

Med Ed 101

JANUARY 17, 2018

I definitely get some questions from students and pharmacists preparing for certification exams. I wanted to put together this Diabetes Medication Comparison Table that highlights really important stuff that you need to remember. The post Diabetes Medication Comparison Table appeared first on Med Ed 101.

Diabetes

Express Pharma

FEBRUARY 7, 2024

billion; Costanza Alciati, Pharma Analyst at GlobalData, offers her view: “ Novo Nordisk has been struggling to meet the demand related to its GLP-1R agonists products, notably Ozempic and Wegovy, approved for type 2 diabetes and obesity respectively.

Diabetes

Pharmaceutical Technology

JULY 12, 2022

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D).

Diabetes

ALiEM - Pharm Pearls

NOVEMBER 8, 2023

The RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) group suggested the following criteria for diagnosing DRESS syndrome and a point scoring system determining negative, possible, probable, or definitive DRESS syndrome [ MDCalc ]: Fever >38.5⸰C

Adverse Reactions

Pharmaceutical Technology

APRIL 25, 2023

Eli Lilly and Company (Lilly) has entered a definitive agreement to sell its dry nasal spray, Baqsimi, to Amphastar Pharmaceuticals for a cash consideration of $500m. Baqsimi is the first and only nasally given glucagon to treat very low blood sugar, or severe hypoglycaemia, in diabetes patients. in global sales reported last year.

Diabetes

Pharmafile

SEPTEMBER 6, 2023

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject to customary closing conditions and is not expected to close until the third quarter of 2023. Financial details of the agreement are yet to be announced.

Diabetes

European Pharmaceutical Review

DECEMBER 1, 2023

There is definitely an interest in advanced therapies, such as cell and gene therapy, plasmids, mRNA, and viral vectors. or 2x, that is definitely seen as a success and [worth] being explored through an oral route. We are certainly seeing requests or demands for large molecules to be explored for oral delivery.

Drug Development

The Thyroid Pharmacist

OCTOBER 7, 2022

I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life.

Diabetes

Med Ed 101

JANUARY 26, 2020

I recently received a text from a friend about the use of oral semaglutide in a patient with diabetes. It is definitely exciting to have more options for patients, even though we know there will inevitably be insurance coverage hurdles to jump through. Here are a few things that you should remember about this first […].

Diabetes

Pharmaceutical Technology

DECEMBER 16, 2022

Sosei Heptares and Eli Lilly and Company have signed a partnership for the discovery, development and commercialisation of small molecules that modulate new G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases.

Diabetes

Pharmafile

DECEMBER 4, 2023

Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire Carmot for an upfront price of $2.7bn as well as milestone payments up to $400m.

Diabetes

Big Molecule Watch

SEPTEMBER 24, 2024

Retatrutide is an investigational product which, according to Lilly, may have potential as an obesity treatment as well as a treatment for type-2 diabetes and other chronic conditions. The FDA determined that, under its regulatory definition, only alpha amino acids are counted towards the “greater than 40 amino acids” threshold.

Dosage

Pharmaceutical Business Review

AUGUST 14, 2023

Lilly signed the definitive agreement to acquire Versanis Bio in July this year. At the time of the deal announcement, its terms specified that shareholders of Versanis were to receive up to $1.92bn in cash, which includes upfront payment and subsequent payments following achievement of some development and sales milestones.

Diabetes

pharmaphorum

JUNE 14, 2021

This can lead to metabolic abnormalities including insulin resistance, diabetes, and elevated levels of blood lipids (such as high cholesterol). They definitely helped get the human story across. Partial lipodystrophy results in a partial loss, but the fat that remains is redistributed in inappropriate places around the body.

Communication

RX Note

JULY 12, 2023

Definition Hypertension is most commonly defined as persistent elevation of systolic BP of 140 mm Hg or greater and/or diastolic BP of 90 mm Hg or greater. However, definition vary by professional organization.

Adverse Reactions

Pulses

AUGUST 3, 2023

Patient is a 19-year old female presenting to the ER with signs and symptoms of DKA (diabetic ketoacidosis) as evidenced by mental disorientation, random blood glucose of 452, persistent nausea and vomiting, and urinalysis positive for ketones. Within the context of healthcare, determining a single definition of empathy is a challenge.

Diabetes

Pharmaceutical Technology

OCTOBER 18, 2022

Oculis has signed a definitive business combination agreement with special purpose acquisition company (SPAC) European Biotech Acquisition (EBAC). Oculis works on developing product candidates for areas with substantial medical needs, including diabetic macular oedema (DME), dry eye disease (DED) and glaucoma.

Diabetes

Pharmaceutical Technology

JULY 21, 2022

ZyVersa Therapeutics has signed a definitive business combination agreement with blank-check special purpose acquisition company (SPAC) Larkspur Health Acquisition. ZyVersa expects that VAR 200 can potentially treat various other glomerular diseases, such as Alport syndrome and diabetic kidney disease.

Diabetes